Navigation Links
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
Date:5/7/2012

NEW YORK, May 7, 2012 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Alexza Pharmaceuticals Inc. ("Alexza Pharmaceuticals" or the "Company") (NasdaqGM: ALXA -News), concerning whether the company and certain of its officers and directors have violated federal securities laws.

On May 4, 2012, shares Alexza Pharmaceuticals fell 20% or 12 cents to close at 49 cents after the FDA denied approval citing manufacturing deficiencies that affected its decision on Adasuve which is a drug designed to rapidly treat agitation related to schizophrenia and bipolar disorder.  Alexza Pharmaceuticals said the FDA won't approve the drug after citing manufacturing problems at a company plant in Mountain View, California.

If you are aware of any facts relating to this investigation, or purchased shares of Alexza Pharmaceuticals, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email eitan@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman, 212-697-6484
eitan@bgandg.com


'/>"/>
SOURCE Bronstein, Gewirtz & Grossman, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Verenium To Present At The Deutsche Bank 2012 Clean Tech, Utilities & Power Conference
2. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
5. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
6. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
7. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
8. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
9. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017 Viverae ® , ... announce the integration of IBM ® Watson Campaign ... deliver targeted communications for a personalized experience. Through digital ... on their health in real time. The enhanced experience ... most to members, wherever they are in their journey ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., ... case series to be presented at the 2017 National ... begins today and continues through April 22. Physicians will ... , used to assess risk for acute kidney injury ... heart failure (ADHF). Elevated levels of ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext ... of collaboration started in 2016, in which Socionext ... Brain SOINN". The companies achieved initial results in ... solution by Artificial Brain SOINN. The results will ... Big Sight, April 19-21, at booths 4505 & ...
Breaking Medicine Technology:
(Date:4/24/2017)... MA (PRWEB) , ... April 24, 2017 , ... ... cardiovascular health of individuals with HIV because it is not known to have ... may have favorable effects to both lower cholesterol levels and dampen inflammation in ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all sorts of ... of them to be very practical. She wanted to write a guide/workbook that would ... their health. It prompted her in writing “ A Clear Path to a Vibrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... ... 2017 , ... Anaconda BioMed, a pre-clinical stage medical device ... of Acute Ischemic Stroke (AIS), today announced it has appointed Creganna Medical to ... regulatory and clinical phases. , "This is another important step for Anaconda Biomed ...
(Date:4/22/2017)... North Carolina (PRWEB) , ... April 22, 2017 , ... ... in the United States estimated to be $394.9 billion. The consequences of rapid ... (and inevitably demolishes) the limits of technology, it is every business and individual’s job ...
Breaking Medicine News(10 mins):